Nutraceuticals
News Releases
2023 December
2023 November
Corporate
Otsuka Pharmaceutical to Sponsor Thematic Project "Resonance of Lives" at the Expo 2025 Osaka, Kansai, Japan
Pharmaceuticals
Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved in the U.S.
Pharmaceuticals
Otsuka Submits New Drug Application in Japan for Voclosporin in the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
MIREVO®, a New Cognitive Function Testing Application for Dementia Care Support, Obtains Regulatory Approval, a First in Japan
Nutraceuticals
Selected as METI's "Model Project for the Promotion of PHR Services" Launch of a Healthcare Service that Improves Health without Conscious Effort
Corporate
Otsuka Pharmaceutical Granted Silver Certification in PRIDE Index 2023 for LGBTQ+ Initiatives
Corporate
Otsuka Announces Personnel Changes
Pharmaceuticals
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
2023 October
Pharmaceuticals
Otsuka Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti® (brexpiprazole)
Corporate
Otsuka Pharmaceutical Receives Eruboshi Grade 3 Certification as an Excellent Company Under the Act on Promotion of Women's Participation and Advancement in the Workplace
Pharmaceuticals
Otsuka Pharmaceutical Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
Nutraceuticals
First PET Bottle and Paper Cup Recycling Initiatives for Tokyo Legacy Half Marathon
Nutraceuticals
Introducing InnerSignal SC Rich Cream- Regulates moisture in the stratum corneum for a higher level of skin care experience -
2023 September
Pharmaceuticals
Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
Corporate
Otsuka Pharmaceutical Enters into Cooperative Agreement with Japan Association of Public Mental Health & Welfare Workers
Pharmaceuticals
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults
Pharmaceuticals
Otsuka Pharmaceutical to Acquire Mindset Pharma - Strengthens pipeline in the area of psychiatric and neurological disorders -
2023 August
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima, Japan -EXCITING SUMMER in WAJIKI and ORONAMIN C DRINK PRESENTS Awa Odori Sound Festival-
Pharmaceuticals
Astex Expands Drug Discovery Collaboration With MSD
Nutraceuticals
POCARI SWEAT X TOKUSHIMA VORTIS Football Dream Project Phase 3Otsuka Pharmaceutical and Tokushima Vortis collaborate in exchange program for junior football players in Cambodia
2023 July
Nutraceuticals
Launch of TCRP NEXT, a New Collaboration Aiming to Promote Total Conditioning- Enhancing sustainable international competitiveness and transitioning from high performance to life performance -
Pharmaceuticals
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia
Corporate
Tokushima Prefecture Signs First Resource Circulation Agreement with Otsuka Pharmaceutical- Promotion of Horizontal PET Bottle Recycling Initiatives -
Nutraceuticals
Otsuka Pharmaceutical Enters into Cooperative Agreementwith Ministry of the Environment
2023 April
Pharmaceuticals
FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII®(aripiprazole), the First, Two-month, Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
Pharmaceuticals
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia
2023 March
Corporate
Otsuka Holdings Selected as Nadeshiko Brand for FY 2022
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 58.6 KB)
Nutraceuticals
New SOYJOY Fruits & Cheese Baked cheesecake-flavored whole-soy nutrition bar with ample fruit
Nutraceuticals
Introducing New UL•OS Scalp Shampoo Volume-up Addresses men's scalp condition and hair problems
Nutraceuticals
New EQUELLE gelée , an Extension of the EQUELLE BrandA convenient, smart solution for midlife transitions
2023 February
Nutraceuticals
Otsuka Pharmaceutical an Official Partner of Tokyo Marathon 2023Providing health management support for runners and officials
Corporate
Otsuka Pharmaceutical Finalizes Agreement with Naruto City and Toyota Tsusho Corporation to Promote Horizontal Recycling of PET bottles
Corporate
Otsuka Pharmaceutical Receives "Consumer-oriented Activity Award" at the 8th ACAP Consumer-oriented Activity Awards - Recognized for ongoing women’s health-care initiatives-
2023 January
Corporate
Otsuka Pharmaceutical Installs Solar Power Generation Systems at Takasaki and Tokushima Itano Factories-Targeting reduction of CO2 emissions-
Pharmaceuticals
Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan
Pharmaceuticals
Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology
Pharmaceuticals
Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer's dementia
2022 December
2022 November
Nutraceuticals
New skin care brand Introducing Sakuraé Double Action Serum - Japan's first "double brightening" effect -
Nutraceuticals
Otsuka Pharmaceutical Finalizes Business Collaboration Agreement for Horizontal Recycling of PET Bottles
Nutraceuticals
Favorable Decision of the Supreme Court on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
Pharmaceuticals
Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225mg for Preventive Treatment of Migraine
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR® gene therapy candidate
Corporate
Otsuka Opens Osaka Research Center for Drug Discovery in Osaka Prefecture, Japan
2022 October
Pharmaceuticals
Avanir Pharmaceuticals, Inc. Business Will Be IntegratedInto Otsuka America Pharmaceuticals, Inc. as of January 1, 2023
Nutraceuticals
Otsuka Pharmaceutical Supports Tokyo Legacy Half Marathon 2022Helping runners to complete the distance and set new records
Pharmaceuticals
Otsuka and Jolly Good to Launch FACEDUO, a Virtual Reality Support Program forPatients with Schizophrenia and Their Supporters
Nutraceuticals
Announcement of Price Revisions for Applicable Products
2022 September
Pharmaceuticals
Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -
Nutraceuticals
Launch of OTSUKA BLUE PLANET in IndonesiaSustainability Program Aims to Contribute to Local Environmental Efforts
Pharmaceuticals
Otsuka announces EC approval of Lupkynis® (voclosporin) as first oral treatment for active lupus nephritis
Nutraceuticals
Launch of SOYJOY Sweet PotatoPopular ingredient flavors new whole-soy nutrition bar
Pharmaceuticals
Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application forAripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia andBipolar I Disorder in Adults
Pharmaceuticals
Otsuka Pharmaceutical announces positive results of phase III trial in Japan for brexpiprazole in the treatment of major depressive disorder
Pharmaceuticals
Otsuka Measurement Kit to be Covered by National Health Insurance in Japan forPhiladelphia-Chromosome-Positive, Acute Lymphoblastic Leukemia
2022 August
Nutraceuticals
Otsuka Subsidiaries Become Official Supporters of ASEAN Football Federation ChampionshipContributing to Safe Tournament Management and Optimum Conditioning for Players and Staf
Nutraceuticals
Announcement of Price Revisions for Applicable Products
Pharmaceuticals
European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for the treatment ofadults with acute myeloid leukemia
Pharmaceuticals
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Nutraceuticals
Presentation of Research Regarding Compounds Contributing to Alleviation of Premenstrual Symptoms
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
2022 July
Pharmaceuticals
Otsuka receives positive CHMP opinion for LupkynisTM (voclosporin)for the treatment of active lupus nephritis
Nutraceuticals
Introducing New B240 TabletsEffortless way to consume a unique ingredient for maintenance of physical condition
Corporate
Full-scale Launch of "Kenkokeiei Tsunagaru Support" ServiceOtsuka Pharmaceutical Supports Resolution of Health Issues for Small & Medium-sized Enterprises
2022 June
Nutraceuticals
POCARI SWEAT 250ml Returnable Bottle For Distribution via Circular Shopping Platform 'Loop'
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
Pharmaceuticals
European Medicines Agency Commences Review of Aripiprazole2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole
Pharmaceuticals
Otsuka Obtains Approval in Japan for Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuticals
Otsuka Enters Collaboration with xFOREST Therapeutics on RNA Structure- Targeted Drug Discovery Covering Multiple Diseases
Nutraceuticals
Otsuka Pharmaceutical Publishes Paper Investigating Binding Property of Salivary IgA on Pathogenic Microorganisms
Pharmaceuticals
Launch in Japan of Moizerto® Ointment, a Treatment for Atopic Dermatitis
2022 May
Nutraceuticals
POCARI SWEAT × TOKUSHIMA VORTIS Football Dream ProjectOtsuka and Tokushima Vortis collaborate to support overseas promotion of health through sports activities and regional vitalization in Tokushima
Pharmaceuticals
Launch in Japan of SAMTASU® for IV Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
Announcement of Termination of Global License Agreements for Renal Anemia Treatment with Akebia Therapeutics, Inc.
Corporate
Four Otsuka Group Companies in Indonesia Adopts CO2-Free Electricity - Approximately 13% reduction in annual CO2 emissions -
2022 April
Pharmaceuticals
Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Application That Uses Eye Tracking Technology
Corporate
Otsuka Group Joins RE100 International Initiative - Committed to 100% Renewable Energy -
Pharmaceuticals
Osaka University and Otsuka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
2022 March
Pharmaceuticals
Akebia Therapeutics Receives Complete Response Letter from U.S. FDAfor Vadadustat for the Treatment of Anemia associated with Chronic Kidney Diseasein Adult Patients
Pharmaceuticals
Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical -
Pharmaceuticals
Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Corporate
Packaging for a Sustainable FuturePOCARI SWEAT to Introduce Recycled PET for Bottles from Spring 2022
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 58.8 KB)
Nutraceuticals
～Otsuka Pharmaceutical Survey of "Working Women's Health Consciousness"～ Indication that women’s health concerns (PMS, menopause) significantly affect career paths. Need for recognition as "corporate issues" beyond individual efforts.
Nutraceuticals
Introducing New Calorie Mate BLOCK VanillaNutritional Balance in Everyday Life for People of All Ages
2022 February
Nutraceuticals
Otsuka Extends Its Deep Expertise in Soy-Based Products to Launch SOYJOY 100% Plant-Based Series
Corporate
Favorable Judgment on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
Corporate
Otsuka Pharmaceutical Certified as Sports Yell Company for 5th Consecutive Year- Collaboration among Otsuka Group Companies to Support Employees' Ongoing Fitness Efforts -
2022 January
Pharmaceuticals
Otsuka Enters Agreement with Jolly Good for Co-Development and Sales Rights in Japanfor a Social Skills Training Platform Using Virtual Reality in the Psychiatric Field
Corporate
Favorable judgment on lawsuit for revocation of trial decision on patent right held in relation to equol-containing foods
Pharmaceuticals
Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients
2021 December
2021 November
Nutraceuticals
Launch of tocoelle Supplement - Gentle support for pre-menstrual fluctuations -
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Corporate
Otsuka Group Supports Recommendations of the Task Force on Climate-related Financial Disclosure (TCFD) -Joins TCFD Consortium-
Pharmaceuticals
Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health Insurance in Japan
2021 October
Pharmaceuticals
Otsuka submits initial marketing authorization application to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
Pharmaceuticals
Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
2021 September
Pharmaceuticals
Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds
Pharmaceuticals
Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis
Pharmaceuticals
Otsuka announces that Novartis Pharma's ENTRESTO® received a new indication for treatment of hypertension in Japan
Corporate
100th Anniversary of Otsuka Group of Companies Looking Ahead to the Next 100 Years
2021 August
Pharmaceuticals
Otsuka to Launch AJOVY® Subcutaneous Injection 225 mg Syringe in Japan
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
Pharmaceuticals
Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets
Pharmaceuticals
Otsuka reports topline outcomes on a phase II trial that evaluated brexpiprazole for the treatment of borderline personality disorder
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at National Junior High School Championships 2021Supporting safe extracurricular sports activities and event operation
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
Nutraceuticals
Production and Sales of Fibe-Mini Begin in Indonesia
2021 July
Nutraceuticals
Reflecting Customer Concerns Introduction of ORONAMIN C DRINK in Label-free Bottles
Nutraceuticals
U.S. Supplement Brand Nature Made Marks 50th Anniversary/Named #1 Pharmacist Recommended Vitamin and Supplement for 24 Years
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at Inter-High 2021 Supporting safe operation and health of competitors and officials for summer Inter-High School Championships
Nutraceuticals
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Uqora, a provider of women's urinary tract health products
Pharmaceuticals
Otsuka Files Application in Japan for Approval of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuticals
Otsuka Pharmaceutical and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China
2021 June
Pharmaceuticals
Otsuka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuticals
Otsuka Has Filed a Marketing Authorization Application to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
AJOVY® Subcutaneous Injection 225 mg Syringe, as a Preventive Treatment of Migraine, Granted Approval in Japan
Pharmaceuticals
Approval in Japan for Otsuka's minor BCR-ABL mRNA measurement kit A marker to monitor treatment effectiveness for acute lymphoblastic leukemia (ALL)
Pharmaceuticals
Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
Corporate
Otsuka Group Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan-
Pharmaceuticals
Otsuka and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
2021 April
Corporate
Otsuka Group Company, A&P Inphatec, Commences Sales in U.S. of XylPhi-PD™,a Bactericidal Treatment for Pierce's Disease in Grapevines
Corporate
Otsuka Pharmaceutical Receives First Certification as Tokyo Metropolitan Government Sports Promotion Model Company (Practical Division) Recognized for providing opportunities for exercise adapted for new lifestyles
Pharmaceuticals
Otsuka and Lundbeck announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
2021 March
Pharmaceuticals
Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia's Vadadustat
Pharmaceuticals
Otsuka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -
Pharmaceuticals
Otsuka Has Filed an Application in Japan for Regulatory Approval of OPC-61815, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB® for Treatment of Acid-Related Disease
Pharmaceuticals
Otsuka and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)
Nutraceuticals
A Delicious Snack That's Good for You Announcing SOYJOY Coffee & Nuts Soy protein from low-GI whole soy
2021 February
Nutraceuticals
Convenient Sizes of UL·OS Medicated Scalp Shampoo and Medicated Skin Wash Launched to Promote Trial Use
Corporate
Otsuka to Construct a Drug Discovery Center in Osaka Prefecture, Japan
Corporate
Office Divisions of Five Otsuka Group Companies to Switch to Green Power
Pharmaceuticals
Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood Cancer
Corporate